The second phase will commence 18 months after the first is completed.
SINGAPORE (Jan 14): Best World has agreed to acquire a 15% stake in Celligenics, a biomedical A*STAR spin-off start-up, in two investment phases.
The first phase will see Best World subscribe for 12.5% of Celligenics shares for $5.625 million, which will be funded by the group’s internal resources.
